Eton Pharmaceuticals, Inc. (ETON)
| Market Cap | 892.72M +92.1% |
| Revenue (ttm) | 86.93M +79.9% |
| Net Income | -1.48M |
| EPS | -0.05 |
| Shares Out | 27.39M |
| PE Ratio | n/a |
| Forward PE | 36.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 523,700 |
| Open | 35.00 |
| Previous Close | 35.00 |
| Day's Range | 32.52 - 35.00 |
| 52-Week Range | 13.09 - 35.66 |
| Beta | 0.82 |
| Analysts | Strong Buy |
| Price Target | 42.67 (+30.93%) |
| Earnings Date | May 14, 2026 |
About ETON
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing vari... [Read more]
Financial Performance
In 2025, Eton Pharmaceuticals's revenue was $79.95 million, an increase of 104.94% compared to the previous year's $39.01 million. Losses were -$4.60 million, 20.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ETON stock is "Strong Buy." The 12-month stock price target is $42.67, which is an increase of 30.93% from the latest price.
News
Eton Pharmaceuticals enters supply, distribution agreement for Impavido
Eton Pharmaceuticals (ETON) announced it has entered into a supply and distribution agreement for the United States commercialization rights to Impavido from an affiliate of Knight Therapeutics. Impav...
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
DEER PARK, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tre...
Eton Pharmaceuticals price target raised to $57 from $52 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Eton Pharmaceuticals (ETON) to $57 from $52 and keeps a Buy rating on the shares. The firm cites the company’s increased fiscal…
Eton Pharmaceuticals Q1 Earnings Call Highlights
Eton Pharmaceuticals NASDAQ: ETON raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and HEMAN...
Eton Pharmaceuticals Earnings Call Transcript: Q1 2026
Record Q1 2026 sales and 73% product revenue growth led to raised full-year guidance above $120 million. New launches of HEMANGEOL and DESMODA, strong portfolio performance, and improved margins position the company for continued growth and profitability.
Eton Pharmaceuticals Earnings release: Q1 2026
Eton Pharmaceuticals released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Eton Pharmaceuticals Quarterly report: Q1 2026
Eton Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 14, 2026.
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 mill...
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
DEER PARK, Ill., May 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tre...
Eton Pharmaceuticals announces relaunch of Hemangeol
Eton Pharmaceuticals (ETON) announced the relaunch of Hemangeol. Hemangeol is the only FDA-approved treatment for infantile hemangioma, a pediatric rare disease that can be time-sensitive. Hemangeol i...
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiation Eton has integrated full Eton Cares patient support, including $0 co-pay for eligibl...
Eton Pharmaceuticals says first patient dosed in study of ET-700
Eton Pharmaceuticals (ETON) announced the first patient has been dosed in a pilot clinical study assessing the efficacy of ET-700, the company’s proprietary, patent-pending formulation of extended-rel...
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...
Eton Pharmaceuticals Proxy statement: Proxy filing
Eton Pharmaceuticals filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Eton Pharmaceuticals appoints Judith Matthews as CFO
Eton Pharmaceuticals (ETON) appointed Judith Matthews as EVP, Accounting and Finance. Matthews will assume the role of CFO effective June 1. The company’s current CFO, James Gruber, will then step…
Eton Pharmaceuticals Announces CFO Succession Plan
Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st
Eton Pharmaceuticals price target raised to $52 from $37 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Eton Pharmaceuticals (ETON) to $52 from $37 and keeps a Buy rating on the shares. Eton “unveiled its second…
Eton Pharmaceuticals price target raised to $35 from $30 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Eton Pharmaceuticals (ETON) to $35 from $30 and keeps a Buy rating on the shares following the company’s comprehensive Q4 update, which included…
Eton Pharmaceuticals price target raised to $31 from $26 at B. Riley
B. Riley raised the firm’s price target on Eton Pharmaceuticals (ETON) to $31 from $26 and keeps a Buy rating on the shares. Following a strong Q4, Eton delivered enhanced…
Eton Pharmaceuticals Earnings Call Transcript: Q4 2025
Revenue more than doubled in 2025, driven by new product launches and strong portfolio growth. Adjusted EBITDA margin rose to 29%, with 2026 revenue expected to exceed $110M and further margin expansion. Strategic acquisitions and label expansions position the company for continued growth.
Eton Pharmaceuticals Annual report: Q4 2025
Eton Pharmaceuticals has published its Q4 2025 annual report on March 19, 2026.
Eton Pharmaceuticals Earnings release: Q4 2025
Eton Pharmaceuticals released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Eton Pharmaceuticals reports Q4 EPS 5c vs. (2c) last year
Reports Q4 revenue $21.28M, consensus $20.58M. “It was another phenomenal quarter for Eton with meaningful contributions from key products across our portfolio including INCRELEX, ALKINDI SPRINKLE, KH...
Eton Pharmaceuticals sees FY26 revenue at least $110M, consensus $105.25M
“We are poised for another year of record financial results in 2026. For the full year, we expect to see revenue exceed $110 million and at least a 30% Adjusted…